ALXP
ALQGC
Market cap5mUSD
Oct 24, Last price
0.07EUR
Name
Quantum Genomics SA
Chart & performance
P/E
—
P/S
502,608.77
EPS
—
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0k
-99.95%
Net income
-9m
L+180.44%
CFO
0
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Quantum Genomics S.A., a biopharmaceutical enterprise headquartered in Paris, France, was established in 2005. The company specializes in advancing therapeutic solutions for cardiovascular ailments. Its drug development efforts are anchored in the brain aminopeptidase A inhibition (BAPAI) platform, primarily targeting hypertension (high blood pressure) and heart failure. Among its pipeline, firibastat is a notable candidate, currently undergoing a crucial Phase III study as a standalone treatment for high blood pressure, and is also progressing through clinical trials for heart failure. Furthermore, Quantum Genomics is developing QGC011 for combination therapy in hypertension, alongside QGC006 and QGC606, which are designed to address both hypertension and heart failure.
Key people
Benoit Gueugnon
Vice President - Finance · since 2020
Olivier Madonna
Medical Director · since 2014
Christian Bechon
Director
Marc Karako
Chief Financial Officer, Director · since 2014
Maurice Salama
Director
Lionel Segard
Chairman of the Board and Chief Executive Officer
Headquarters & legal address
6 RUE CAMBACERES
PARIS 75008
FR
PARIS 75008
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||